Navigation Links
PDL BioPharma Announces Fourth Quarter and Full Year 2012 Financial Results
Date:3/1/2013

INCLINE VILLAGE, Nev., March 1, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the fourth quarter and full year ended December 31, 2012.

(Logo:  http://photos.prnewswire.com/prnh/20110822/SF55808LOGO)

Total revenues in 2012 were $374.5 million, compared to $362.0 million in 2011, with royalty revenues increasing seven percent over full year 2011. For the fourth quarter of 2012, total revenues were $86.0 million, compared to $72.8 million in the fourth quarter of 2011.

Royalty revenues for the fourth quarter of 2012 are based on third quarter product sales by PDL's licensees. The fourth quarter 2012 revenue growth was primarily driven by increased royalties from third quarter 2012 sales of Herceptin® and Avastin®, which are marketed by Genentech and Roche.  Royalty revenue for the fourth quarter and 2012 are net of payments made under our February 2011 settlement agreement with Novartis Pharma AG.

Operating expenses in 2012 were $25.5 million, compared with $18.3 million in 2011. For the fourth quarter of 2012, general and administrative expenses were $7.7 million compared with $4.8 million for the same period of 2011.

Net income in 2012 was $211.7 million, or $1.45 per diluted share as compared with net income of $199.4 million in 2011 or $1.15 per diluted share. Net income for the fourth quarter of 2012 was $49.4 million or $0.34 per diluted share as compared with net income of $38.9 million or $0.24 per diluted share for the same period of 2011.

Net cash provided by operating activities in 2012 was $210.2 million, compared with $169.8 million in 2011. At December 31, 2012, PDL had cash, cash equivalents and investments of $148.7 million, compared with $227.9 million at
'/>"/>

SOURCE PDL BioPharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Biopharma M&A Trends Hold Steady, But Deals Declined in 2011
2. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
3. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
4. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
5. Genesis Biopharma Announces Termination of Previously Announced Proposed Public Offering
6. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
7. S1 Biopharma Expands Focus to Include Male Sexual Health
8. New Study Details Foreign Efforts To Lure Biopharmaceutical Companies
9. Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA Congress
10. Cell Therapeutics Aequus BioPharma Validates its Proprietary GlycoPolymer Technology for the Extension of the Half-life of Therapeutic Protein Drugs
11. Galena Biopharma, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 31, 2015 Pepperl+Fuchs, a world leader ... Corporation, a leading provider of HART protocol devices. ... further extend its integrated solutions offerings and strengthen ... "We are pleased to add the MACTek ... Jim Bolin , Pepperl+Fuchs, executive vice president ...
(Date:8/31/2015)... , Aug. 31, 2015  Ascendant Solutions, Inc. ... today announced that its Healthcare subsidiary, Dougherty,s Holdings, has ... on the downtown square of Springtown, Texas ... than 35 years, this community-based pharmacy has provided retail ... of Springtown . The ...
(Date:8/31/2015)... 2015  Daktari Diagnostics today announced a collaboration with Merck, ... and Canada , to develop Daktari,s ... up to $8.5 million over the next 3.5 years, will ... regulatory approval of Daktari,s HCV test. The ... can detect low levels of virus directly in a single ...
Breaking Medicine Technology:Ascendant Solutions, Inc. Announces Completion of Fifth Pharmacy Acquisition by Its Dougherty's Holdings Subsidiary 2Ascendant Solutions, Inc. Announces Completion of Fifth Pharmacy Acquisition by Its Dougherty's Holdings Subsidiary 3Daktari Enters Collaboration Agreement with Merck to Develop Test for Hepatitis C Virus 2Daktari Enters Collaboration Agreement with Merck to Develop Test for Hepatitis C Virus 3
... grounds, direct programming is superior,to cloning as a ... Nov. 20 Two major scientific,papers published this ... way to,generate patient-matched human pluripotent stem cells without ... or human or animal eggs.,Research groups in Wisconsin ...
... 20 The following statement,was released today by ... the Elizabeth Glaser Pediatric AIDS Foundation:, "Four ... Relief,(PEPFAR) began funding treatment and prevention, today,s report ... remains a devastating worldwide,pandemic, we are beginning to ...
Cached Medicine Technology:Two Major Studies Show: Human Pluripotent Stem Cells without Cloning or Destroying Embryo 2Two Major Studies Show: Human Pluripotent Stem Cells without Cloning or Destroying Embryo 3New UNAIDS Report Offers Encouraging News, But Most HIV-Positive Mothers Still Not Getting the Care & Treatment They Need 2
(Date:8/31/2015)... ... ... When it comes to undergoing a hair transplant, most patients have donor hair moved from ... to the hair on top of the scalp, as well as filling in areas missing ... hair on other areas of their head. , What about patients who have a limited, ...
(Date:8/31/2015)... ... August 31, 2015 , ... India Network Foundation, a ... ” tool, which summarizes all available plans, plan maximums, pre-existing condition coverage limits ... to help India Network members make an informed decision regarding the care they ...
(Date:8/31/2015)... IL (PRWEB) , ... August 31, 2015 , ... The ... that Firm Partner William Scott has been nominated by his peers to earn a ... less than five percent of attorneys in the state of Illinois. The nomination process ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... one-day event geared to patients and family members, medical professionals, and researchers, covering ... mesothelioma experts. The conference is a collaborative effort between the Mesothelioma Applied ...
(Date:8/31/2015)... , ... August 31, 2015 , ... ... Vice President, Marketing and Corporate Communications. In this capacity, Michael will provide strategic ... is an industry leader in consumer-focused programs that have contributed to the company’s ...
Breaking Medicine News(10 mins):Health News:Body Hair Transplants to Help Achieve a Full Head of Hair 2Health News:India Network proudly launches the new InstantQuote tool to help choose right visitor health insurance with pre-existing conditions to US bound visitors 2Health News:DuPage County Family Law Attorney Named Illinois Leading Lawyer 2Health News:New York Experts on Mesothelioma Come Together at Memorial Sloan Kettering Cancer Center 2Health News:New York Experts on Mesothelioma Come Together at Memorial Sloan Kettering Cancer Center 3Health News:CareSource Names Vice President, Marketing and Corporate Communications 2
... U.S. hospitals and doctors competing on the ... basis of quality, cost and service., ... specialty network for high value medical procedures such as coronary,artery ... excellence throughout the United States. These providers and facilities,meet specific ...
... Medicare Part D has improved drug,coverage and lessened ... says a new study released today by Avalere Health ... the first to use a large, national claims dataset ... utilization and,out-of-pocket costs for enrollees with type 2 diabetes. ...
... five-year study at the University of Texas Medical Branch ... two most common diseases of young children: colds and ... March 15 issue of Clinical Infectious Disease, confirmed the ... of young children, viral colds and ear infections. It ...
... ATLANTAThe American Cancer Society invites medical and science reporters to ... York City to learn whats new in the fight against ... the American Cancer Society. This informative media briefing will offer ... as in cancer research, prevention, early detection, patient services, and ...
... Orthotopic liver transplantation (OLT) is associated with severe bleeding ... this severe bleeding in OLT. Hemostatic abnormalities remain a ... led by Professor Wang Xuehao, is to be published ... Journal of Gastroenterology. , Aprotinin, a serine protease inhibitor, ...
... Administrator to U.S. Insurers Strengthens its ... Providers, Physicians and Patients, BERKELEY HEIGHTS, N.J., ... ), a worldwide provider of secure workflow,management software ... of the nation,s leading mobility benefit providers to,national ...
Cached Medicine News:Health News:The Healthplace America(TM) Benefit Delivers a Better Option in Healthcare 2Health News:Avalere Study Shows Medicare Part D Helping People with Type 2 Diabetes; Warns People with Diabetes of Probability of Reaching the 'Donut Hole' 2Health News:Avalere Study Shows Medicare Part D Helping People with Type 2 Diabetes; Warns People with Diabetes of Probability of Reaching the 'Donut Hole' 3Health News:Researchers confirm link between common cold and ear infection 2Health News:American Cancer Society science reporters briefing to feature latest developments in cancer 2Health News:American Cancer Society science reporters briefing to feature latest developments in cancer 3Health News:Wheelchair Professionals Selects Authentidate's Inscrybe Healthcare Platform to Streamline Mobility Order Processing 2Health News:Wheelchair Professionals Selects Authentidate's Inscrybe Healthcare Platform to Streamline Mobility Order Processing 3Health News:Wheelchair Professionals Selects Authentidate's Inscrybe Healthcare Platform to Streamline Mobility Order Processing 4
This is an Immunological assay intended for the quantitative in vitro determination of haemoglobin A1c (HbA1c) in whole blood....
For the quantitative in vitro determination of Potassium in serum or plasma....
Immunoturbidimetric assay for the quantitative in vitro determination of Lipoprotein (a) in human serum or plasma...
For the quantitative in vitro determination of Valproic Acid in human serum...
Medicine Products: